Ignite Creation Date:
2024-05-05 @ 11:28 PM
Last Modification Date:
2024-10-26 @ 10:34 AM
Study NCT ID:
NCT01339975
Status:
COMPLETED
Last Update Posted:
2019-08-05
First Post:
2011-04-20
Brief Title:
Level of Expression and Prognostic Value of CXCL4 CXCL4L1 and CXCR3 in Renal Cell Carcinoma
Sponsor:
University Hospital Bordeaux
Organization:
University Hospital Bordeaux
Study Overview
Official Title:
Level of Expression and Prognostic Value of CXCL4 CXCL4L1 and CXCR3 in Renal Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2019-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ChemoRenCan
Brief Summary:
Despite novel treatment options Renal Cell Carcinoma RCC has been characterized by a constant increase in its mortality and consequently requires an important involvement in translational research
The aim of this study is to evaluate the interest of CXCL4 CXCL4L1 and CXCR3 as biomarkers in localized locally advanced or metastatic RCC Indeed these chemokines have shown anti-angiogenic and anti-tumor properties in experimental models and may be particularly interesting for prognostic and predictive purposes
The aim of this study is to evaluate the interest of CXCL4 CXCL4L1 and CXCR3 as biomarkers in localized locally advanced or metastatic RCC Indeed these chemokines have shown anti-angiogenic and anti-tumor properties in experimental models and may be particularly interesting for prognostic and predictive purposes
Detailed Description:
Based on a physiopathological rationale the use of RCC-directed antiangiogenic therapies into clinical practice leads to conclusive results and makes RCC a particularly well-suited tumor type to study factors involved in the angiogenic process Furthermore the intensive use of targeted therapies in clinical practice raised new questions about their management
Therefore the identification of new molecular biomarkers is important
to improve the precision of prognostic models currently based on clinical biological or histopathological variables
to identify high risk patients that could benefit from an adjuvant treatment or a closer postoperative follow-up
to predict the response to antiangiogenic therapies and therefore identify the drug which is likely to be the most effective within an ever increasing pharmacopeia
to follow the therapy as precisely as possible predict or attest the disease progression justifying a therapeutic modification
Low CXCL4 CXCL4L1 and CXCR3 tumor expression levels are associated with bad prognosis factors in RCC Consequently their interest in RCC is worth being evaluated in two subgroups Localized locally advanced renal cell carcinoma and Metastatic renal cell carcinoma
Therefore the identification of new molecular biomarkers is important
to improve the precision of prognostic models currently based on clinical biological or histopathological variables
to identify high risk patients that could benefit from an adjuvant treatment or a closer postoperative follow-up
to predict the response to antiangiogenic therapies and therefore identify the drug which is likely to be the most effective within an ever increasing pharmacopeia
to follow the therapy as precisely as possible predict or attest the disease progression justifying a therapeutic modification
Low CXCL4 CXCL4L1 and CXCR3 tumor expression levels are associated with bad prognosis factors in RCC Consequently their interest in RCC is worth being evaluated in two subgroups Localized locally advanced renal cell carcinoma and Metastatic renal cell carcinoma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None